Initiss Plus (Cilazapril, Hydrochlorothiazide)

Cilazapril blocks the enzyme that converts angiotensin I to angiotensin II, leading to vasodilation and reduced vascular resistance. Hydrochlorothiazide acts on the kidney’s distal tubules to inhibit sodium and chloride reabsorption, promoting diuresis and decreasing blood‑volume, which together produce a synergistic blood‑pressure‑lowering effect.

The specific dose of Initiss Plus is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and other individual factors. Patients should follow the dosage instructions provided by their healthcare professional and not adjust the dose on their own.

The safety of Initiss Plus in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with single‑component ACE inhibitors or thiazide diuretics, Initiss Plus offers the convenience of a fixed‑dose combination, potentially improving adherence and providing a more pronounced blood‑pressure reduction. However, clinicians must consider individual patient tolerance, renal function, and electrolyte balance when choosing between combination therapy and separate agents.

Initiss Plus tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiration date.

Initiss Plus is taken orally, usually once daily, with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Serious risks include angioedema (swelling of the face, lips, tongue, or throat), severe dehydration or electrolyte disturbances, acute kidney injury, marked hypotension, and rare blood disorders such as agranulocytosis. Patients should seek immediate medical attention if they experience symptoms like swelling, difficulty breathing, sudden weakness, or unexplained bruising.

Initiss Plus should be avoided in patients with a known hypersensitivity to cilazapril, hydrochlorothiazide, or any component of the formulation. It is also contraindicated in individuals with severe renal impairment, anuria, or a history of angioedema related to ACE‑inhibitor therapy.